EUVIMEDEUVIMED entdecken
Crossref

Prevotella ‐Derived Butyrate Inhibits CD8 + T‐Cell Glycolysis via AKT / mTOR Signalling to Alleviate MASH

Feixiang Xiong iD, Fengna Yan, Yuyong Jiang iD, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang iD, Dandan Chen, Yixin Hou iD

Liver International · 2026-04 · 46 (4)

DOI: 10.1111/liv.70613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 24.03.2026. Verfasst von Feixiang Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Glycolysis, CD8-Positive T-Lymphocytes, Butyrates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Metabolic associated steatohepatitis (MASH) is a critical stage of MAFLD, lacking effective therapies. Gut microbiota and their metabolites, particularly short‐chain fatty acids (SCFAs), are increasingly recognised as modulators of hepatic metabolism and immune responses. We investigated whether Prevotella could ameliorate MASH by regulating CD8 + T‐cell metabolism.

Methods

Faecal samples from MASH patients and healthy controls were analysed by 16S rDNA sequencing and untargeted metabolomics. MASH mouse models, germ‐free mice and ex vivo CD8 + T‐cell cultures were used to assess the effects of Prevotella and butyrate on glycolysis, PI3K/AKT/mTOR signalling and liver pathology. Metabolic activity was measured using ECAR, 2‐NBDG uptake and lactate production; molecular changes were evaluated by qPCR, western blotting and flow cytometry.

Results

16S rDNA sequencing revealed a significant reduction of Prevotella abundance in MASH patients compared with healthy controls, which was inversely correlated with hepatic steatosis and CD8 + T‐cell infiltration. In MCD diet‐induced MASH mice, oral administration of Prevotella alleviated hepatic lipid accumulation and collagen deposition. In germ‐free mice, colonisation with Prevotella similarly improved liver histology. Mechanistically, Prevotella suppressed glycolytic activity in CD8 + T cells, as shown by decreased 2‐NBDG uptake, ECAR measurements and reduced expression of glycolytic enzymes (HK2, PKM2, LDHA). Additionally, Prevotella downregulated the PI3K/AKT/mTOR signalling pathway in CD8 + T cells, linking its metabolic effects to immune modulation. Notably, the combination of Prevotella with a glycolysis inhibitor did not further enhance its therapeutic efficacy compared with Prevotella alone, indicating that suppression of glycolysis is a major mechanism underlying Prevotella 's protective effects.

Conclusion

Prevotella mitigates MASH by downregulating the PI3K/AKT/mTOR–glycolysis axis in CD8 + T cells via butyrate‐dependent mechanisms, highlighting its potential as a microbial therapeutic candidate for MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesGlycolysisCD8-Positive T-LymphocytesButyratesPrevotellaAnimalsProto-Oncogene Proteins c-aktSignal TransductionHumansMiceMaleDisease Models, AnimalMice, Inbred C57BLGastrointestinal MicrobiomeFemalePhosphatidylinositol 3-KinasesLiverFeces

Stichwörter der Autor:innen

CD8+ T cellsMASHPI3K/AKT/mTOR signallingPrevotellaglycolysis

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktButyratesMTOR protein, humanPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Beijing Institute of Infectious Diseases, Beijing, China.
  • National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Beijing Key Laboratory of Viral Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Feixiang Xiong, Yuyong Jiang, Xuejie Zhang, Yixin Hou

Zitieren

APA

Xiong, F., Yan, F., Jiang, Y., Ji, X., Wu, T., Zhou, Y., Zhang, X., Chen, D., & Hou, Y. (2026). Prevotella ‐Derived Butyrate Inhibits CD8 + T‐Cell Glycolysis via AKT / mTOR Signalling to Alleviate MASH. Liver International, 46(4). https://doi.org/10.1111/liv.70613

Vancouver

Xiong F, Yan F, Jiang Y, Ji X, Wu T, Zhou Y, et al. Prevotella ‐Derived Butyrate Inhibits CD8 + T‐Cell Glycolysis via AKT / mTOR Signalling to Alleviate MASH. Liver International. 2026;46(4). doi:10.1111/liv.70613

BibTeX
@article{Xiong2026,
  author = {Xiong, Feixiang and Yan, Fengna and Jiang, Yuyong and Ji, Xiaomin and Wu, Tong and Zhou, Yang and Zhang, Xuejie and Chen, Dandan and Hou, Yixin},
  title = {Prevotella ‐Derived Butyrate Inhibits CD8 + T‐Cell Glycolysis via AKT / mTOR Signalling to Alleviate MASH},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {4},
  doi = {10.1111/liv.70613}
}
Kostenlos starten →